191348-04-6

Basic information

• Product Name: (S)-tert-butyl 3-formylpyrrolidine-1-carboxylate
• Synonyms: (S)-tert-butyl 3-formylpyrrolidine-1-carboxylate;(3S)-3-Formyl-1-pyrrolidinecarboxylic acid tert-butyl ester;S-1-Boc-3-pyrrolidinecarbaldehyde;(S)-3-forMyl-1-Boc-pyrrolidine
• CAS NO: 191348-04-6
• Molecular Formula: C10H17NO3
• Molecular Weight: 199.248
• Mol File: 191348-04-6.mol

Chemical Properties

• Boiling Point: 276.3±33.0 °C(Predicted)
• Appearance: /
• Density: 1.148
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.44±0.40(Predicted)
• CAS DataBase Reference: (S)-tert-butyl 3-formylpyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 3-formylpyrrolidine-1-carboxylate(191348-04-6)
• EPA Substance Registry System: (S)-tert-butyl 3-formylpyrrolidine-1-carboxylate(191348-04-6)

Safety Data

• Hazardous Substances Data: 191348-04-6(Hazardous Substances Data)

Usage

Uses

(S)-tert-Butyl 3-formylpyrrolidine-1-carboxylate is a useful research chemical.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 138108-72-2 tert-butyl (R)-3-hydroxymethylpyrrolidine-1-carboxylate 
• 201230-82-2 carbon monoxide 
• 73286-71-2 N-(tert-butoxycarbonyl)-2,3-dihydropyrrole 
• 140148-70-5 (S)-1-N-boc-β-proline 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 146348-14-3 methyl 5-oxo-1-((S)-1-phenylethyl)pyrrolidine-3-(S)-carboxylate 
• 173724-95-3 (S)-1-((S)-1-phenylethyl)-3-hydroxymethylpyrrolidine 
• 97-65-4 2-methylenesuccinic acid 
• 173340-19-7 (3S)-1-((S)-1-phenylethyl)-5-oxo-3-pyrrolidinecarboxylic acid 
• 85310-69-6 pyrrolidin-3-ylmethanol 
• 617-52-7 Dimethyl itakonate 
• 35309-35-4 5-oxopyrrolidine-3-carboxylic acid methyl ester 
• 569667-93-2 tert-butyl 3-(methoxy(methyl)carbamoyl)pyrrolidine-1-carboxylate 

Downstream Products

• 138108-72-2 tert-butyl (R)-3-hydroxymethylpyrrolidine-1-carboxylate 
• 72925-16-7 1-boc-pyrrolidine-3-carboxylic acid 
• 114214-69-6 tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 270912-72-6 tert-butyl 3-(aminomethyl)pyrrolidine-1-carboxylate 
• 1588423-77-1 C₁₈H₂₆ClN₃O₄ 
• 1588423-78-2 C₁₆H₂₄ClN₃O₃ 
• 1588423-79-3 C₁₆H₂₂ClN₃O₃ 

Relevant articles and documents

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1 H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia

BCR-ABL kinase inhibition is an effective strategy for the treatment of chronic myeloid leukemia (CML). Herein, we report compound 3a-P1, bearing a difluoro-indene scaffold, as a novel potent pan-inhibitor against BCR-ABL mutants, including the most refractory T315I mutant. As the privileged (S)-isomer compared to its (R)-isomer 3a-P2, 3a-P1 exhibited potent antiproliferative activities against K562 and Ku812 CML cells and BCR-ABL and BCR-ABLT315I BaF3 cells, with IC50 values of 0.4, 0.1, 2.1, and 4.7 nM, respectively. 3a-P1 displayed a good safety profile in a battery of assays, including single-dose toxicity, hERG K+, and genotoxicity. It also showed favorable mice pharmacokinetic properties with a good oral bioavailability (32%), a reasonable half-life (4.61 h), and a high exposure (1386 h·ng/mL). Importantly, 3a-P1 demonstrated a higher potency than ponatinib in a mice xenograft model of BaF3 harboring BCR-ABLT315I. Overall, the results indicate that 3a-P1 is a promising drug candidate for the treatment of CML to overcome the imatinib-resistant T315I BCR-ABL mutation.

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

CDK9 Kinase inhibitors

The present application relates to CDK9 kinase inhibitors which provide a compound of formula (I) or a stereoisomer thereof. A solvate, a metabolite, a pharmaceutically acceptable salt or prodrug, and a pharmaceutical composition comprising the same. Also provided are the use of compounds and pharmaceutical compositions in the manufacture of a medicament for the treatment of cancer.

TEAD INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

Facile synthesis of 7-alkyl-1,2,3,4-tetrahydro-1,8-naphthyridines as arginine mimetics using a Horner-Wadsworth-Emmons-based approach

Integrin inhibitors based on the tripeptide sequence Arg-Gly-Asp (RGD) are potential therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Herein, we describe an expeditious three-step synthetic sequence of Horner-Wadsworth-Emmons olefination, diimide reduction, and global deprotection to synthesise cores for these compounds in high yields (63-83% over 3 steps) with no need for chromatography. Key to this transformation is the phosphoramidate protecting group, which is stable to metalation steps.

C11-CYCLIC SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF

Provided are 13-membered macrolides for the treatment of infectious diseases. The 13- membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13-membered macrolides, pharmaceutical compositions comprising the 13-

Nickel-Catalyzed Selective Reduction of Carboxylic Acids to Aldehydes

The direct reduction of carboxylic acids to aldehydes is a fundamental transformation in organic synthesis. The combination of an air-stable Ni precatalyst, dimethyl dicarbonate as an activator, and silane reductant effects this reduction for a wide variety of substrates, including pharmaceutically relevant structures, in good yields and with no overreduction to alcohols. Moreover, this methodology is scalable, allows access to deuterated aldehydes, and is also compatible with one-pot utilization of the aldehyde products.

Boosting the hydrolytic stability of phosphite ligand in hydroformylation by the construction of superhydrophobic porous framework

The development of a catalyst that delivers high activities and selectivities with excellent durability is of great importance. Numerous efficient catalysts suffer from the inherent hydrolysis liabilities, plaguing their practical applications. Herein, we show that this challenge can be tackled by constructing them into superhydrophobic porous frameworks, as exemplified by a water-sensitive phosphite ligand, tris(2-tert-butylphenyl) phosphite. The efficiency and long-term stability of the developed system are remarkably high in the hydroformylation of internal olefins after metalation with Rh species, superior to the corresponding homogeneous analogues. The significantly boosted hydrolytic stability allows for catalytic transformations using water as a green solvent, which not only facilitates the isolation of the products, but also furnishes the aldehydes with higher regioselectivities for the desired linear form in comparison with that operated under benchmark conditions using toluene as a reaction medium. Given these promising results, we anticipate the strategy advanced herein will form the basis for constructive perspectives in the enhancement of the water resistance of catalysts and the development of high performance hydroformylation catalysts.